Evidence map›Paper›PMID 29250437›Full record

ArticleNPJ vaccines2017

Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection.

Kristien Van Reeth, José Carlos Mancera Gracia, Ivan Trus, Lieve Sys, Gerwin Claes, Han Versnaeyen, Eric Cox, Florian Krammer, Yu Qiu

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Vaccine design via antigen reorientation.Nature chemical biology · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Kristien Van ReethLaboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Gent, Belgium.
José Carlos Mancera GraciaLaboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Gent, Belgium.
Ivan TrusLaboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Gent, Belgium.
Lieve SysLaboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Gent, Belgium.
Gerwin ClaesLaboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Gent, Belgium.
Han VersnaeyenLaboratory of Pathology, Faculty of Veterinary Medicine, Ghent University, Gent, Belgium.
Eric CoxLaboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Gent, Belgium.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yu QiuOIE Sub-Regional Representation for South-East Asia, Bangkok, Thailand.
Ghent University · BEIcahn School of Medicine at Mount Sinai · USUNICEF East Asia and Pacific Regional Office · TH

Funding

NIAID NIH HHS HHSN266200700010C
6 · The paper itself

Abstract

The emergence of multiple novel lineages of H1 and H3 influenza A viruses in swine has confounded control by inactivated vaccines. Because of substantial genetic and geographic heterogeneity among circulating swine influenza viruses, one vaccine strain per subtype cannot be efficacious against all of the current lineages. We have performed vaccination-challenge studies in pigs to examine whether priming and booster vaccinations with antigenically distinct H3N2 swine influenza viruses could broaden antibody responses and protection. We prepared monovalent whole inactivated, adjuvanted vaccines based on a European and a North American H3N2 swine influenza virus, which showed 81.5% aa homology in the HA1 region of the hemagglutinin and 83.4% in the neuraminidase. Our data show that (i) Priming with European and boosting with North American H3N2 swine influenza virus induces antibodies and protection against both vaccine strains, unlike prime-boost vaccination with a single virus or a single administration of bivalent vaccine. (ii) The heterologous prime-boost vaccination enhances hemagglutination inhibiting, virus neutralizing and neuraminidase inhibiting antibody responses against H3N2 viruses that are antigenically distinct from both vaccine strains. Antibody titers to the most divergent viruses were higher than after two administrations of bivalent vaccine. (iii) However, it does not induce antibodies to the conserved hemagglutinin stalk or to other hemagglutinin subtypes. We conclude that heterologous prime-boost vaccination might broaden protection to H3N2 swine influenza viruses and reduce the total amount of vaccine needed. This strategy holds potential for vaccination against influenza viruses from both humans and swine and for a better control of (reverse) zoonotic transmission of influenza viruses.

Identifiers

PMID29250437
PMCPMC5604745
OpenAlexW2606155606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.